In the Press

Featured
Recent

2018 Harrington Scholar-Innovators Selected

CLEVELAND, OHIO, January 18 – Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, part of The Harrington Project for Discovery & Development, has announced its 2018 Harrington Scholar-Innovator Award recipients.  The 10...

Social Finance Forum: Navigating Impact in Health

TORONTO, November 2017 – Baiju Shah joined international leaders in the social finance and impact investing space for the 10th Annual Social Finance Forum. He represented BioMotiv on the Navigating Impact in Health panel to discuss innovative approaches to the drug...

Collaboration in Action: Drug Discovery Alliance Models

BOSTON, November 2017 —  The Association of Strategic Alliance Professionals hosted the 2017 BioPharma Conference. BioMotiv’s Senior Vice President, Technical Operations, Chuck McOsker, PhD, represented BioMotiv on the panel discussing Strategic Perspectives on...

Koutif Therapeutics Launched to Treat Inflammatory Diseases

CLEVELAND AND PITTSBURGH, September 21, 2017 –  BioMotiv, a drug development accelerator, and the University of Pittsburgh announced the launch of Koutif Therapeutics, which is developing an inhibitor of an E3 ligase (Fbxo3) to treat inflammatory conditions such...

Allinaire Awarded $1.9M in Grant Funding

CLEVELAND and INDIANAPOLIS, September 19, 2017 – Allinaire Therapeutics has been awarded a $1,670,000 Phase II SBIR grant from the National Heart, Lung, and Blood Institute (NHLBI) and a $213,000 Discovery Award from the Department of Defense (DOD). The funding...

Nature Features Sujana’s Technology

CLEVELAND, June 5, 2017 – Nature Communications has published the research of Daniel I. Simon, M.D.; Edward Plow, Ph.D.; and Yunmei Wang, Ph.D. – Founders of Sujana Biotech – which describes a novel target for thrombotic disorders that does not...

Cell Features OptiKira’s Technology for Reversing Diabetes

CLEVELAND, April 26, 2017 – OptiKira founders Dr. Feroz Papa (UCSF), Dr. Bradley Backes (UCSF), and Dr. Dustin Maly (University of Washington) have published research showing that direct targeting of IRE1α, using mono-selective KIRA8, reverses autoimmune...

Takeda, HDI Partner to Advance Rare Diseases Treatments

Harrington Discovery Institute (HDI) and Takeda Pharmaceuticals have teamed up to support the translation of research into treatments for rare diseases. The alliance builds on HDI’s model and results in a dedicated rare-disease funding track that will benefit from...

2017 Harrington Prize for Innovation in Medicine Awarded

CLEVELAND, OH – March 15, 2017 The Harrington Discovery Institute and The American Society for Clinical Investigation are pleased to announce that the 2017 Harrington Prize for Innovation in Medicine has been jointly awarded to Daniel J. Drucker, MD of Mt. Sinai...